Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 23

Results For "biosimilar"

228 News Found

Cadila Healthcare divests animal health business: ICICI Securities
News | May 16, 2021

Cadila Healthcare divests animal health business: ICICI Securities

The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.


Dr. Reddy's Sputnik V India price is Rs. 995.40
News | May 15, 2021

Dr. Reddy's Sputnik V India price is Rs. 995.40

The company is working closely with its six manufacturing partners in India


Pharma sector has both brainpower and manpower to drive growth: Mandaviya
Policy | April 09, 2021

Pharma sector has both brainpower and manpower to drive growth: Mandaviya

The government has taken all the effective measures to make healthcare affordable


GlaxoSmithKline approves sale of Vemgal plant
News | April 05, 2021

GlaxoSmithKline approves sale of Vemgal plant

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS


Pharma 4.0: Pandemic pushed reluctant pharma companies to adopt advanced technologies
News | March 04, 2021

Pharma 4.0: Pandemic pushed reluctant pharma companies to adopt advanced technologies

Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.


Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr
News | January 23, 2021

Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr

EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business


Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn
News | January 08, 2021

Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn

Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.